花园生物成立于2000年12月，公司于2014年10月9日在深交所创业板挂牌上市。经过二十多年的发展， 花园生物已经完成了维生素D3全产业链的布局。公司四大类产品精制羊毛脂、羊毛脂胆固醇、维生素 D3、25-羟基维生素D3的产能规模都处于全球领先位置。 2025年上半年，花园生物营业收入约6.35亿元，同比增加5.86%;归母净利润约1.62亿元，同比增加 13.67%。 10月10日，花园生物在互动平台向投资者表示，公司2025年第三季度报告预约披露日为2025年10月18 日，具体业绩情况您可关注公司届时披露的定期报告。花园药业目前主要专注于心血管、神经系统等慢 性疾病领域仿制药的研发、生产和销售，暂未涉及创新药。 ...

Core Viewpoint - The company, Huayuan Biological, is a major global producer of lanolin cholesterol and is committed to continuously optimizing its production processes and technologies to enhance its competitive advantage [2]. Company Summary - Huayuan Biological is recognized as one of the leading producers of lanolin cholesterol globally [2]. - The company is focused on improving its production techniques and technological capabilities [2].

Group 1 - The company Garden Biologics (300401.SZ) is a major producer of lanolin cholesterol and aims to continuously optimize its production processes and technology to enhance its competitive advantage [2] - The company has scheduled to disclose its semi-annual report for 2025 on August 16, 2025, which investors are encouraged to monitor for further insights [2]